With 1.74 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.63 million shares. During the session, the Medical Care Facilities company that operates in wider Healthcare sector, reached to the highest price of $123.65 whereas the lowest price it dropped to was $118.98. The 52-week range on THC shows that it touched its highest point at $171.20 and its lowest point at $92.01 during that stretch. It currently has a 1-year price target of $172.43. THC paid its most recent dividend on 952905600, while the ex-dividend date for that was 952905600. Beta for the stock currently stands at 1.68.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of THC was up-trending over the past week, with a rise of 0.12%, but this was down by -6.52% over a month. Three-month performance dropped to -9.95% while six-month performance fell -26.13%. The stock gained 29.90% in the past year, while it has lost -4.10% so far this year. A look at the trailing 12-month EPS for THC yields 32.23 with Next year EPS estimates of 13.22. For the next quarter, that number is 3.13. This implies an EPS growth rate of 2.30% for this year and 8.78% for next year.
Float and Shares Shorts:
At present, 95.11 million THC shares are outstanding with a float of 92.29 million shares on hand for trading. On 2025-03-31, short shares totaled 2.43 million, which was 256.0 higher than short shares on 1740700800. In addition to Dr. Saumya Sutaria M.D. as the firm’s Chairman & CEO, Mr. Sun K. Park serves as its Executive VP & CFO.
Institutional Ownership:
Through their ownership of 0.99328005 of THC’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-12-31, THC reported revenue of $5072000000.0 and operating income of $777000000.0. The EBITDA in the recently reported quarter was $1085000000.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for THC since 10 analysts follow the stock currently. There are 9 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With THC analysts setting a high price target of 217.0 and a low target of 134.0, the average target price over the next 12 months is 170.6459. Based on these targets, THC could surge 79.26% to reach the target high and rise by 10.7% to reach the target low. Reaching the average price target will result in a growth of 40.97% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $11.46073 being high and $11.13214 being low. For THC, this leads to a yearly average estimate of $11.32133. Based on analyst estimates, the high estimate for the next quarter is $2.83 and the low estimate is $2.33. The average estimate for the next quarter is thus $2.64.
